diclofenac has been researched along with Cardiovascular Stroke in 54 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The popular over-the counter analgesic drug diclofenac has recently been associated with increased rates of myocardial infarction among patients with cardiovascular risk as well as among healthy populations." | 8.86 | A Review on the risk of myocardial infarction associated with the NSAID diclofenac. ( Krötz, F; Struthmann, L, 2010) |
| "Tramadol has been widely used among patients with osteoarthritis (OA); however, there is paucity of information on its cardiovascular risk." | 7.96 | Association of tramadol with risk of myocardial infarction among patients with osteoarthritis. ( Choi, HK; Dubreuil, M; LaRochelle, MR; Lei, G; Lin, J; Lu, N; Tomasson, G; Wei, J; Wood, MJ; Zeng, C; Zhang, Y, 2020) |
| "A patient in whom acute myocardial infarction developed during diclofenac-induced anaphylaxis is described." | 7.75 | Acute ST-segment elevation myocardial infarction associated with diclofenac-induced anaphylaxis: case report. ( de Groot, JW; Gosselink, AT; Ottervanger, JP, 2009) |
| "To explore further a recent finding that long-term users of diclofenac are at increased risk of acute myocardial infarction (AMI) similar to users of rofecoxib and celecoxib." | 7.74 | Diclofenac and acute myocardial infarction in patients with no major risk factors. ( Jick, H; Jick, SS; Kaye, JA, 2007) |
| "Celecoxib and rofecoxib were associated with different odds of MI." | 5.33 | Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005) |
| " An increased risk of acute myocardial infarction and heart failure is observed with all NSAIDs, while an elevated risk of hemorrhagic stroke appears to be restricted to the use of diclofenac and meloxicam." | 5.01 | Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? ( Al-Daghri, N; Bruyère, O; Chapurlat, R; Cooper, C; Herrero-Beaumont, G; Rannou, F; Reginster, JY; Roth, R; Uebelhart, D, 2019) |
| " Keywords: nonsteroidal anti-inflammatory drugs, cardiovascular diseases, cardiovascular risk, lornoxicam, diclofenac sodium, thrombo-elastogram, myocardial infarction, stroke." | 5.01 | Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk. ( Khovasova, NO; Naumov, AV; Tkacheva, ON, 2019) |
| "The popular over-the counter analgesic drug diclofenac has recently been associated with increased rates of myocardial infarction among patients with cardiovascular risk as well as among healthy populations." | 4.86 | A Review on the risk of myocardial infarction associated with the NSAID diclofenac. ( Krötz, F; Struthmann, L, 2010) |
| " We used a Mantel-Haenszel method to obtain odds ratios (ORs) of the association between NSAID use (ibuprofen, naproxen, or diclofenac) and MACE (myocardial infarction, ischemic stroke, heart failure, or all-cause death)." | 4.31 | Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study. ( Bonnesen, K; Ehrenstein, V; Grønkjær, MS; Hallas, J; Lash, TL; Pedersen, L; Schmidt, M; Sørensen, HT, 2023) |
| " After applying these weights in a pooled logistic regression, we estimated hazard ratios (HRs) of the association between use of NSAIDs (ibuprofen, naproxen, or diclofenac) and cardiovascular events (a composite of myocardial infarction, ischemic stroke, congestive heart failure, atrial fibrillation or flutter, and all-cause death)." | 4.31 | Impact of hemoglobin A1c level on the association between non-steroidal anti-inflammatory drug use and cardiovascular events in patients with type 2 diabetes: A population-based cohort study. ( Bonnesen, K; Ehrenstein, V; Lash, TL; Pedersen, L; Schmidt, M; Sørensen, HT, 2023) |
| "Tramadol has been widely used among patients with osteoarthritis (OA); however, there is paucity of information on its cardiovascular risk." | 3.96 | Association of tramadol with risk of myocardial infarction among patients with osteoarthritis. ( Choi, HK; Dubreuil, M; LaRochelle, MR; Lei, G; Lin, J; Lu, N; Tomasson, G; Wei, J; Wood, MJ; Zeng, C; Zhang, Y, 2020) |
| "A 62-year-old male smoker with no other comorbidities presented to emergency department with systemic anaphylaxis, due to oral diclofenac for toothache." | 3.79 | Cardiac anaphylaxis: a case of acute ST-segment elevation myocardial infarction after IM epinephrine for anaphylactic shock. ( Chandrashekaran, R; Ganeshwala, G; Maniyal, VK; Mathew, N; Tummala, K, 2013) |
| "We evaluated 2-year CV outcomes in a prospective, nested biomarker study among patients (N = 6273) with rheumatoid arthritis and osteoarthritis treated with NSAID in the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) trial." | 3.77 | Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. ( Brune, K; Cannon, CP; Contant, CF; Curtis, SP; Jarolim, P; Kaur, A; Laine, L; Morrow, DA; Ren, F; Ruff, CT, 2011) |
| "This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
| "A patient in whom acute myocardial infarction developed during diclofenac-induced anaphylaxis is described." | 3.75 | Acute ST-segment elevation myocardial infarction associated with diclofenac-induced anaphylaxis: case report. ( de Groot, JW; Gosselink, AT; Ottervanger, JP, 2009) |
| " Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0." | 3.75 | Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009) |
| "To investigate the risk of myocardial infarction (MI) with diclofenac, ibuprofen and naproxen, taking into account the exposure patterns." | 3.74 | Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? ( Leufkens, HG; Rietbrock, S; Setakis, E; van Staa, TP, 2008) |
| "To evaluate the association between rofecoxib, celecoxib, diclofenac, and ibuprofen and the risk of hospitalization for acute myocardial infarction (AMI) in an elderly population." | 3.74 | Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. ( Kong, SX; LeLorier, J; Rahme, E; Toubouti, Y; Watson, DJ, 2007) |
| "To explore further a recent finding that long-term users of diclofenac are at increased risk of acute myocardial infarction (AMI) similar to users of rofecoxib and celecoxib." | 3.74 | Diclofenac and acute myocardial infarction in patients with no major risk factors. ( Jick, H; Jick, SS; Kaye, JA, 2007) |
| "To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis." | 3.73 | Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006) |
| " An increased risk was observed for diclofenac and rofecoxib, the latter one with a clear dose-response trend." | 2.43 | Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. ( García Rodríguez, LA; Hernández-Díaz, S; Varas-Lorenzo, C, 2006) |
| "Naproxen was not associated with any increase (adjusted OR 1." | 1.48 | Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. ( Choi, HK; Dubreuil, M; Louie-Gao, Q; Neogi, T; Peloquin, CE; Zhang, Y, 2018) |
| "We propose a practical group sequential method, a conditional sequential sampling procedure, to test if a drug of interest (D) leads to an elevated risk for an adverse event E compared with a comparison drug C." | 1.35 | A conditional sequential sampling procedure for drug safety surveillance. ( Li, L, 2009) |
| "Celecoxib and rofecoxib were associated with different odds of MI." | 1.33 | Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. ( Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL, 2005) |
| "Naproxen was associated with an OR of 0." | 1.32 | Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. ( García Rodríguez, LA; González-Pérez, A; Maguire, A; Varas-Lorenzo, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 2 (3.70) | 18.2507 |
| 2000's | 22 (40.74) | 29.6817 |
| 2010's | 23 (42.59) | 24.3611 |
| 2020's | 6 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Baak, BN | 1 |
| Jick, SS | 4 |
| Bonnesen, K | 2 |
| Pedersen, L | 2 |
| Ehrenstein, V | 2 |
| Grønkjær, MS | 1 |
| Sørensen, HT | 2 |
| Hallas, J | 2 |
| Lash, TL | 2 |
| Schmidt, M | 3 |
| Ernst, MT | 1 |
| Pottegård, A | 1 |
| Wei, J | 1 |
| Wood, MJ | 1 |
| Dubreuil, M | 3 |
| Tomasson, G | 1 |
| LaRochelle, MR | 1 |
| Zeng, C | 1 |
| Lu, N | 1 |
| Lin, J | 1 |
| Choi, HK | 2 |
| Lei, G | 1 |
| Zhang, Y | 3 |
| Moore, N | 1 |
| Seo, KW | 1 |
| Park, JS | 1 |
| Tahk, SJ | 1 |
| Shin, JH | 1 |
| Dalal, D | 1 |
| Peloquin, C | 1 |
| Neogi, T | 2 |
| Choi, H | 1 |
| Felson, D | 1 |
| Chen, YR | 1 |
| Hsieh, FI | 1 |
| Chang, CC | 1 |
| Chi, NF | 1 |
| Wu, HC | 1 |
| Chiou, HY | 1 |
| Louie-Gao, Q | 1 |
| Peloquin, CE | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Masclee, GMC | 1 |
| Straatman, H | 1 |
| Arfè, A | 1 |
| Castellsague, J | 2 |
| Garbe, E | 1 |
| Herings, R | 1 |
| Kollhorst, B | 1 |
| Lucchi, S | 1 |
| Perez-Gutthann, S | 1 |
| Romio, S | 1 |
| Schade, R | 1 |
| Schink, T | 1 |
| Schuemie, MJ | 1 |
| Scotti, L | 1 |
| Varas-Lorenzo, C | 4 |
| Valkhoff, VE | 1 |
| Villa, M | 1 |
| Sturkenboom, MCJM | 1 |
| Cooper, C | 1 |
| Chapurlat, R | 1 |
| Al-Daghri, N | 1 |
| Herrero-Beaumont, G | 1 |
| Bruyère, O | 1 |
| Rannou, F | 1 |
| Roth, R | 1 |
| Uebelhart, D | 1 |
| Reginster, JY | 1 |
| Naumov, AV | 1 |
| Tkacheva, ON | 1 |
| Khovasova, NO | 1 |
| Tummala, K | 2 |
| Maniyal, VK | 2 |
| Chandrashekaran, R | 1 |
| Mathew, N | 1 |
| Ganeshwala, G | 1 |
| Bhala, N | 1 |
| Emberson, J | 1 |
| Merhi, A | 1 |
| Abramson, S | 1 |
| Arber, N | 1 |
| Baron, JA | 1 |
| Bombardier, C | 1 |
| Cannon, C | 1 |
| Farkouh, ME | 1 |
| FitzGerald, GA | 1 |
| Goss, P | 1 |
| Halls, H | 1 |
| Hawk, E | 1 |
| Hawkey, C | 1 |
| Hennekens, C | 1 |
| Hochberg, M | 1 |
| Holland, LE | 1 |
| Kearney, PM | 1 |
| Laine, L | 2 |
| Lanas, A | 1 |
| Lance, P | 1 |
| Laupacis, A | 1 |
| Oates, J | 1 |
| Patrono, C | 1 |
| Schnitzer, TJ | 1 |
| Solomon, S | 1 |
| Tugwell, P | 1 |
| Wilson, K | 1 |
| Wittes, J | 1 |
| Baigent, C | 1 |
| Senthilkumaran, S | 1 |
| Menezes, RG | 1 |
| Ibrahim, SM | 1 |
| Thirumalaikolundusubramanian, P | 1 |
| Uehara, Y | 1 |
| Murata, Y | 1 |
| Shiga, S | 1 |
| Hosoi, Y | 1 |
| van Staa, TP | 1 |
| Rietbrock, S | 1 |
| Setakis, E | 1 |
| Leufkens, HG | 1 |
| Merkely, B | 1 |
| Tóth-Zsamboki, E | 1 |
| Becker, D | 1 |
| Beres, BJ | 1 |
| Szabó, G | 1 |
| Vargova, K | 1 |
| Fülöp, G | 1 |
| Kerecsen, G | 1 |
| Preda, I | 1 |
| Spaulding, C | 1 |
| Kiss, RG | 1 |
| de Groot, JW | 1 |
| Gosselink, AT | 1 |
| Ottervanger, JP | 1 |
| Li, L | 1 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Murray, KT | 1 |
| Stein, CM | 1 |
| Daugherty, JR | 1 |
| Arbogast, PG | 1 |
| García-Rodríguez, LA | 1 |
| Krötz, F | 1 |
| Struthmann, L | 1 |
| Ruff, CT | 1 |
| Morrow, DA | 1 |
| Jarolim, P | 1 |
| Ren, F | 1 |
| Contant, CF | 1 |
| Kaur, A | 1 |
| Curtis, SP | 1 |
| Cannon, CP | 1 |
| Brune, K | 1 |
| Schjerning Olsen, AM | 1 |
| Fosbøl, EL | 2 |
| Lindhardsen, J | 2 |
| Folke, F | 2 |
| Charlot, M | 1 |
| Selmer, C | 1 |
| Lamberts, M | 1 |
| Bjerring Olesen, J | 1 |
| Køber, L | 3 |
| Hansen, PR | 2 |
| Torp-Pedersen, C | 3 |
| Gislason, GH | 3 |
| Bavry, AA | 1 |
| Khaliq, A | 1 |
| Gong, Y | 1 |
| Handberg, EM | 1 |
| Cooper-Dehoff, RM | 1 |
| Pepine, CJ | 1 |
| Grimaldi-Bensouda, L | 1 |
| Rossignol, M | 1 |
| Danchin, N | 1 |
| Steg, PG | 1 |
| Bessede, G | 1 |
| Ovize, M | 1 |
| Cottin, Y | 1 |
| Autret-Leca, E | 1 |
| Benichou, J | 1 |
| Abenhaim, L | 1 |
| Naimer, S | 1 |
| Alla, VM | 1 |
| Kanuri, S | 1 |
| Esterbrooks, D | 1 |
| Altman, R | 1 |
| Gonzalez, CD | 1 |
| Olsen, AM | 1 |
| Andersson, C | 1 |
| Nielsen, MB | 1 |
| Blanco, VM | 1 |
| Möller, I | 1 |
| Catalán, F | 1 |
| Casares, G | 1 |
| García Rodríguez, LA | 2 |
| Maguire, A | 1 |
| González-Pérez, A | 1 |
| Kimmel, SE | 1 |
| Berlin, JA | 1 |
| Reilly, M | 1 |
| Jaskowiak, J | 1 |
| Kishel, L | 1 |
| Chittams, J | 1 |
| Strom, BL | 1 |
| Wieckhorst, A | 1 |
| Tiroke, A | 1 |
| Lins, M | 1 |
| Reinecke, A | 1 |
| Herrmann, G | 1 |
| Krüger, D | 1 |
| Simon, R | 1 |
| Hernández-Díaz, S | 1 |
| Jacobsen, S | 1 |
| Rasmussen, JN | 1 |
| Rasmussen, S | 1 |
| Buch, P | 1 |
| Friberg, J | 1 |
| Schramm, TK | 1 |
| Abildstrom, SZ | 1 |
| Madsen, M | 1 |
| Schneeweiss, S | 1 |
| Solomon, DH | 1 |
| Wang, PS | 1 |
| Rassen, J | 1 |
| Brookhart, MA | 1 |
| Rahme, E | 1 |
| Watson, DJ | 1 |
| Kong, SX | 1 |
| Toubouti, Y | 1 |
| LeLorier, J | 1 |
| Kaye, JA | 2 |
| Jick, H | 2 |
| Chen, LC | 1 |
| Ashcroft, DM | 1 |
| Singh, H | 1 |
| Sim, TB | 1 |
| Hennekens, CH | 1 |
| Borzak, S | 1 |
| Viigimaa, M | 1 |
| Jôudu, T | 1 |
| Hendrikson, E | 1 |
| Shandrik, Y | 1 |
| Teesalu, R | 1 |
| Koren, W | 1 |
| Shahar, A | 1 |
| Boulanger, CM | 1 |
| Scoazec, A | 1 |
| Ebrahimian, T | 1 |
| Henry, P | 1 |
| Mathieu, E | 1 |
| Tedgui, A | 1 |
| Mallat, Z | 1 |
| Michot, F | 1 |
| Ajdacic, K | 1 |
| Glaus, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466] | 0 participants (Actual) | Interventional | 2021-04-29 | Withdrawn (stopped due to Inadequate funding) | |||
| Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001] | Phase 4 | 60 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.[NCT01910116] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| Single and Repeated Leech Therapy for the Treatment of Late Stage Knee Osteoarthritis. A Randomized, Placebo Controlled Comparative Trial[NCT00435773] | Phase 2 | 118 participants | Interventional | 2004-02-29 | Completed | ||
| The Impact of Microparticles on Inflammatory Responses During Visceral and Cardiac Surgery[NCT00677781] | 108 participants (Actual) | Observational | 2008-02-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11 |
| Placebo | -2.9 |
"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.9 |
| Placebo | -4.8 |
"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -6.8 |
| Placebo | -3.7 |
"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.7 |
| Placebo | -4.8 |
"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).~AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -2.2 |
"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.6 |
| Placebo | -8.0 |
"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -15.6 |
| Placebo | -4.4 |
"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -13.4 |
| Placebo | -2.2 |
"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -14.0 |
| Placebo | -11.0 |
"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.0 |
"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -6.0 |
"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12.0 |
| Placebo | -6 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baselie and 16 weeks
| Intervention | participants (Number) |
|---|---|
| Shinbaro | 55 |
| Placebo | 40 |
"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -11.0 |
| Placebo | -6.0 |
"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -8.5 |
"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -9.0 |
| Placebo | -3.0 |
"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -10.0 |
| Placebo | -6.0 |
"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -19.0 |
| Placebo | -13 |
"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -6.5 |
"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -12 |
| Placebo | -7.0 |
"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Shinbaro | -16.0 |
| Placebo | -11.5 |
"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | 0 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -2.0 |
| Placebo | -1.0 |
"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | joints (Median) |
|---|---|
| Shinbaro | -1 |
| Placebo | 0 |
"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | Joints (Median) |
|---|---|
| Shinbaro | -1.0 |
| Placebo | -1.0 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 12 weeks and 16 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 2 | 104 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 4 weeks and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 7 | 99 |
| Shinbaro | 10 | 99 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 8 weeks and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 4 | 105 |
yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: Baseline 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Placebo | 4 | 102 |
| Shinbaro | 7 | 102 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 43 | 63 |
| Shinbaro | 62 | 47 |
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| responder | nonresponder | |
| Placebo | 38 | 68 |
| Shinbaro | 56 | 53 |
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 4 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Nonresponder | |
| Placebo | 32 | 74 |
| Shinbaro | 48 | 61 |
7 reviews available for diclofenac and Cardiovascular Stroke
| Article | Year |
|---|---|
Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiotoxicity; Cardiovascular Diseases; Cyclooxygenase 2 I | 2020 |
Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diclofenac; Gastrointestinal Diseases; Humans; | 2019 |
Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclo | 2019 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor | 2013 |
A Review on the risk of myocardial infarction associated with the NSAID diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; M | 2010 |
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cohort Studies; Diclofenac; Dose-Resp | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Re | 2007 |
1 trial available for diclofenac and Cardiovascular Stroke
| Article | Year |
|---|---|
A double-blind clinical trial to determine if an interaction exists between diclofenac sodium and the oral anticoagulant acenocoumarol (nicoumalone).
Topics: Acenocoumarol; Angina Pectoris; Arthritis, Rheumatoid; Diclofenac; Double-Blind Method; Drug Interac | 1975 |
46 other studies available for diclofenac and Cardiovascular Stroke
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinical Practice Research Datalink.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; Humans; Ibuprofen; Myocar | 2022 |
Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cross-Over Studies; Diclofe | 2023 |
Impact of hemoglobin A1c level on the association between non-steroidal anti-inflammatory drug use and cardiovascular events in patients with type 2 diabetes: A population-based cohort study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Diabetes Mellitus, Type 2; Diclofena | 2023 |
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cohort Studies; Diclofenac; Heart | 2023 |
Association of tramadol with risk of myocardial infarction among patients with osteoarthritis.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Codeine; Diclo | 2020 |
A Case of Acute Myocardial Infarction Induced by Selective Cyclooxygenase-2 Inhibitor.
Topics: Calcium Channel Blockers; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Male; Middle Aged; Myocar | 2017 |
Meloxicam and risk of myocardial infarction: a population-based nested case-control study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chi-Square Distribution; | 2017 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2018 |
Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclo | 2018 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Diclofenac; | 2018 |
Cardiac anaphylaxis: a case of acute ST-segment elevation myocardial infarction after IM epinephrine for anaphylactic shock.
Topics: Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Epinephrine; Humans; Injections, I | 2013 |
Cardiac anaphylaxis: searching for clarity.
Topics: Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Epinephrine; Humans; Male; Myocard | 2014 |
Reply to the letter to the editor.
Topics: Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Epinephrine; Humans; Male; Myocard | 2014 |
NSAIDs diclofenac, indomethacin, and meloxicam highly upregulate expression of ICAM-1 and COX-2 induced by X-irradiation in human endothelial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Cyclooxygenase 2; Diclofenac; E-Selectin | 2016 |
Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dr | 2008 |
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inh | 2009 |
Acute ST-segment elevation myocardial infarction associated with diclofenac-induced anaphylaxis: case report.
Topics: Anaphylaxis; Diclofenac; Humans; Male; Middle Aged; Myocardial Infarction | 2009 |
A conditional sequential sampling procedure for drug safety surveillance.
Topics: Aged; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Evaluation; Drug-Related Si | 2009 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C | 2009 |
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein | 2011 |
Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cohor | 2011 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; | 2011 |
Letter by Naimer regarding article, "Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Male; Myocardial Infarction | 2011 |
Letter by Alla et al regarding article, "Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Male; Myocardial Infarction | 2011 |
Letter by Altman and Gonzalez regarding article, "Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Male; Myocardial Infarction | 2011 |
Cardiovascular risks mount with certain anti-inflammatory drugs. Diclofenac is cited as the most dangerous anti-inflammatory drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Health Behavior; Humans; Myocardial Infarction; | 2010 |
Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Denmark; Diclofenac; Female; Follow-Up Studies; Hospi | 2013 |
[Acute myocardial infarction during a diclofenac-associated anaphylactic reaction].
Topics: Anaphylaxis; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dr | 2003 |
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Case- | 2004 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confo | 2005 |
[Acute coronary syndrome after diclofenac induced coronary spasm].
Topics: Acute Disease; Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Coronary Disease; Di | 2005 |
[New epidemiologic data show: conventional NSAIDs need individual benefit-risk evaluation].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cyclooxygenase 2 Inhibitors; Denmark; | 2005 |
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; C | 2006 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F | 2006 |
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Stu | 2007 |
Cardiovascular safety of cyclo-oxygenase-2 inhibitors.
Topics: Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Myocardial Infarction; Pyridines; Randomi | 2007 |
Diclofenac and acute myocardial infarction in patients with no major risk factors.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Mal | 2007 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
NSAIDS-induced anaphylaxis precipitating acute coronary vasospasm.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Coronary Vasospasm; Diclofenac; Emergenc | 2008 |
Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2008 |
Antiaggregative therapy with acetylsalicylic acid and diclofenac in patients with acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Diclofenac; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggrega | 1994 |
Xiphodynia masking acute myocardial infarction: a diagnostic cul-de-sac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chest Pain; Creatine Kinase; Diagnosis, Differential; Diclo | 1998 |
The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cyclooxygenase 2; Cyclooxygenase 2 In | 2000 |
Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction.
Topics: Adult; Animals; Aorta; Cell Membrane; Cell Membrane Structures; Cyclooxygenase Inhibitors; Diclofena | 2001 |